AJMC - Change is Coming

AJMC - Change is Coming

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 11, 2024

MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.

Episodes in this series

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

EP. 1 NCCN Guidelines Update Adds Mirvetuximab Soravtansine Plus Bevacizumab for FRα-Expressing, Platinum-Sensitive Ovarian Cancer

Video 1 - "NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer"

EP. 2 NCCN Guidelines: Implementing New Therapy Options for Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 3 Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 4 MIRASOL trial and DESTINY-PanTumor02 Trial Overview

Video 2 - "Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer"

EP. 5 Tailored Therapy: Decision Making for Ovarian Cancer Treatment

Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"

EP. 6 Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment

Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"

EP. 7 Closing Thoughts on the Current Ovarian Cancer Treatment Landscape

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Global connection concept-S-stock.adobe.com.jpeg

Photobiomodulation, Bio-Machines, and the Future of Dermatology

ByGiuliana Grossi

January 30th 2026

Addressing the Fragmentation of MS Care: Kavita Nair, PhD

ByKavita V. Nair, PhD

January 30th 2026

Glaucoma awareness month | Image credit: khaled - stock.adobe.com

Glaucoma Awareness Month Shines Light on Eye Condition Known as the Silent Thief

ByJulia Bonavitacola,Jullia Rosdahl, MD, PhD,Ariana Levin, MD,Manjool Shah, MD

January 30th 2026

Image credit: Yurii Kibalnik-stock.adobe.com

Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026

ByGiuliana Grossi

January 29th 2026

Manjool Shah, MD

Treatment for Glaucoma Continues to Evolve, Allowing Eye Doctors to Personalize Treatment: Manjool Shah, MD

ByJulia Bonavitacola,Manjool Shah, MD

January 29th 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Trending on AJMC

AI-Supported Mammography Caught More Cancers During Screening

The Strategic Necessity of Pharma-MedTech Convergence in an Era of Precision Medicine

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026

Photobiomodulation, Bio-Machines, and the Future of Dermatology

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.